

[← News](#)

PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy

6 June 2025

Treatment with semaglutide should be stopped if NAION occurs

[News](#)[Human](#)[Medicines](#)[Pharmacovigilance](#) [Share](#)

This news announcement was revised on 13 June 2025 to delete the reference to the European Commission issuing a legally binding decision on the procedure.

EMA's safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause loss of vision. Semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used in the treatment of diabetes and obesity (namely Ozempic, Rybelsus and Wegovy).

After reviewing all available data on NAION with

semaglutide, including data from non-clinical studies, [clinical trials](#), post-marketing surveillance and the medical literature, [PRAC](#) has concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide).

Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in the risk of developing NAION compared with people not taking the medicine. This corresponds to approximately one additional case of NAION per 10,000 person-years of treatment; one person-year corresponds to one person taking semaglutide for one year. Data from [clinical trials](#) also point to a slightly higher risk of developing the condition in people taking semaglutide, compared with people taking placebo (a dummy treatment).

EMA has therefore recommended that the [product information](#) for semaglutide medicines is updated to include NAION as a side effect with a frequency of 'very rare'. If patients experience a sudden loss of vision or rapidly worsening eyesight during treatment with semaglutide, they should contact their doctor without delay. If NAION is confirmed, treatment with semaglutide should be stopped.

More about the medicines

Semaglutide, a GLP-1 receptor agonist, is the [active substance](#) in certain medicines used in the treatment of diabetes and obesity (namely Ozempic, Rybelsus and Wegovy). Semaglutide acts in the same way as GLP-1 (a natural hormone in the body) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels. Semaglutide also regulates appetite by increasing a person's feelings of fullness, while reducing their food intake, hunger and cravings.

More about the procedure

The potential association between exposure to semaglutide and NAION (non-arteritic anterior ischemic optic neuropathy) was evaluated as part of a post-authorisation

measure (LEG) resulting from a PSUR assessment.

The review has been carried out by the [Pharmacovigilance Risk Assessment Committee \(PRAC\)](#), the Committee responsible for the evaluation of safety issues for human medicines, which has made a set of recommendations.

The [PRAC](#) recommendations will now be sent to the [Committee for Medicinal Products for Human Use \(CHMP\)](#), responsible for questions concerning medicines for human use, which will adopt the Agency's opinion.

Related content

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee \(PRAC\) 2-5 June 2025](#)

Contact point

Media enquiries

Tel. +31 (0)88 781 8427

E-mail: press@ema.europa.eu

All other enquiries

please submit your request via the [online form](#)

Follow us on [Bluesky](#)

Related medicine information

[Ozempic](#)

[Rybelsus](#)

[Wegovy](#)

Share this page



E-mail



LinkedIn



BlueSky



Facebook



More share options

**Product emergency hotline
OUTSIDE WORKING HOURS**

[About us](#)

[What we do](#)

[Careers](#)

[Committees & working parties](#)

[Regulatory network](#)

[European experts](#)

[Languages](#)

[Frequently asked questions](#)

[Glossaries](#)

[About this website](#)

[Cookies](#)

[Website data protection notice](#)

[Data protection at EMA](#)

[Search tips](#)

[Access to documents](#)

[Contacts](#)

[Send a question](#)

[EMA Service Desk \(system support\)](#)

[Services and databases](#)

[European Medicines Agency](#)

[Domenico Scarlattilaan 6](#)

[1083 HS Amsterdam](#)

[The Netherlands](#)

[Tel: +31 \(0\)88 781 6000](#)

[How to find us](#)

[Postal address and deliveries](#)

[Business hours and holidays](#)

[RSS Feed](#)

[Bluesky](#)

YouTube

LinkedIn

© 1995 - 2025 European Medicines Agency

European Union agencies network

An agency of the European Union